AlphAIAlphAI — Financial news for AI agents
zacks.com$MRNA

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

Original reporting
zacks.com
Published Nov 6, 2026, 5:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises — source image
Source · zacks.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The earnings beat and raised outlook provide a clear catalyst for short‑term price appreciation, while the company's cash position and upcoming trial data add longer‑term considerations.

02

Market read

A large‑cap biotech delivering an earnings surprise and upgraded guidance is a notable market mover, especially given the ongoing demand for COVID vaccines and a robust cash balance.

03

What to watch

Potential headwinds from regulatory scrutiny of mRNA patents and the mixed results in other pipeline programs.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Moderna's Q3 results highlight a turnaround from a loss to profit, driven by higher international COVID‑19 vaccine sales and cost reductions.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna reported Q3 2026 earnings beat, posted a profit of $0.38 EPS versus a $1.10 loss estimate and raised its 2026 revenue growth outlook to 15-25%.

Expected impact

likely upward pressure as investors price in stronger earnings and higher growth outlook

Evidence & confidence

The surprise profit and raised guidance are fresh primary disclosures for a large‑cap biotech, creating a clear short‑term catalyst.

Market effects

Sector

Biotech and vaccine developers may see broader sentiment lift from Moderna's strong COVID vaccine sales and guidance.

Regional

U.S. markets likely open higher on the news; international markets may react to the overseas revenue growth.

Global

Moderna's global vaccine sales and new product pipeline could influence global health‑sector sentiment.

Counterpoint

What could challenge this read

Investors may question the sustainability of COVID vaccine demand and the impact of pending litigation costs.

Key entities

  • company
    Moderna

    Biotech firm developing mRNA vaccines and therapeutics.

  • partner
    Merck

    Collaborator on the intismeran cancer therapy program.

Read at source← All news

StoryModerna reports Q3 profit and raises 2026 revenue-growth outlook

Also covered by

5 outlets

Related articles

$MRNAMedAI 8/10

WHO adds two more Ebola vaccines to clinical trial

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

finance.yahoo.com
$MRNAMedAI 8/10

Moderna enjoys stable vaccine sales thanks to global COVID uptake

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

biospace.com
$MRNAHighAI 8/10

What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna reported a 27% drop in R&D expenses to $583M in Q3, while SG&A expenses rose 5% to $282M. The company reduced its full-year R&D and capital expenditure estimates. Cash and investments increased to $8B. Moderna expects year-end cash of $8.1B-$8.3B. It announced progress in melanoma, renal cell carcinoma, and pancreatic cancer studies, and received FDA approval for its flu vaccine mFLUSIVA. The norovirus vaccine candidate did not meet interim success criteria.

finance.yahoo.com